Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Kolesnik, E; Scherr, D; Rohrer, U; Benedikt, M; Manninger, M; Sourij, H; von, Lewinski, D.
SGLT2 Inhibitors and Their Antiarrhythmic Properties.
Int J Mol Sci. 2022; 23(3):
Doi: 10.3390/ijms23031678
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Kolesnik Ewald
- Scherr Daniel
- Co-Autor*innen der Med Uni Graz
- Benedikt Martin
- Manninger-Wünscher Martin
- Rohrer Ursula
- Sourij Harald
- von Lewinski Dirk
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Sodium-glucose cotransporter 2 (SGLT2) inhibitors are gaining ground as standard therapy for heart failure with a class-I recommendation in the recently updated heart failure guidelines from the European Society of Cardiology. Different gliflozins have shown impressive beneficial effects in patients with and without diabetes mellitus type 2, especially in reducing the rates for hospitalization for heart failure, yet little is known on their antiarrhythmic properties. Atrial and ventricular arrhythmias were reported by clinical outcome trials with SGLT2 inhibitors as adverse events, and SGLT2 inhibitors seemed to reduce the rate of arrhythmias compared to placebo treatment in those trials. Mechanistical links are mainly unrevealed, since hardly any experiments investigated their impact on arrhythmias. Prospective trials are currently ongoing, but no results have been published so far. Arrhythmias are common in the heart failure population, therefore the understanding of possible interactions with SGLT2 inhibitors is crucial. This review summarizes evidence from clinical data as well as the sparse experimental data of SGLT2 inhibitors and their effects on arrhythmias.
- Find related publications in this database (Keywords)
- SGLT2 inhibitors
- atrial fibrillation
- arrhythmias
- ventricular arrhythmias